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Abstract
Background: The impact of BRAF tumor mutations on the natural course of disease of melanoma patients is controversial.
Patients and Methods: We analyzed the mutational status and overall survival of 215 patients receiving treatment with
dacarbazine or temozolomide. All patients who started first-line treatment at our institution between 2000 and 2010 were
included to prevent selection and bias due to thereafter arising therapeutic options.
Results: No patient received BRAF- or MEK-inhibitors during follow-up. Survival was associated with the pattern of visceral
involvement, the presence of brain metastases and the serum lactate dehydrogenase level (all p,0.001). The BRAF-V600
mutational status was not associated with survival and no differences in overall survival were detected according to age,
gender or to the cytotoxic agent used for therapy. In Cox regression analysis the presence of brain metastases (hazard ratio
2.3; p,0.001) and an elevated serum LDH (hazard ratio 2.5; p,0.001) were the only factors, which independently predicted
survival.
Conclusions: No differences in prognosis were observed according to the BRAF mutational status in patients with distant
metastasis treated with monochemotherapy.
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Introduction
BRAF-V600 tumor mutations constitutively activate the mito-
gen-activated protein kinase (MAPK) signaling pathway leading to
an enhanced mitotic activity [1,2]. Blocking the activated pathway
by specific inhibitors leads to impressive clinical responses and an
improved survival of advanced melanoma patients [3–5]. Never-
theless, the prognostic relevance of BRAF mutations in the natural
course of disease is controversial [6–18]. A trend towards worse
survival of metastatic patients with BRAF mutation was observed
in two Australian cohorts and in a study performed in the United
States [7–9]. Similarly, a poorer survival of metastatic patients
with BRAF or NRAS tumor mutations [10] and of patients with
BRAF-mutant tumors after treatment with temozolomide and
bevacizumab [11] was reported before. In contrast, Edlundh-Rose
et al. did not find any association between the tumor NRAS or
BRAF genotype and survival after occurrence of metastasis [12].
The aim of the present study was to investigate the prognostic
impact of BRAF-V600 tumor mutations in melanoma patients
receiving first-line treatment with dacarbazine or temozolomide
during the years 2000–2010, before availability of BRAF inhibitors.
We present the first survival analysis of melanoma patients
focusing on the BRAF mutational status of an unselected real life
cohort.
Materials and Methods
Ethics Statement
All patients had given their written informed consent to have
clinical data recorded by the Central Malignant Melanoma
Registry (CMMR) registry. The institutional ethics committee
Tu¨bingen approved the study (ethic vote 047/2013BO2).
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Patients
Patients with invasive cutaneous melanoma treated at the
University Department of Dermatology Tu¨bingen (Germany)
were identified in the Central Malignant Melanoma Registry
(CMMR) database. Of 319 patients who received first-line
systemic treatment with dacarbazine or temozolomide between
2000 and 2010, formalin-fixed paraffin-embedded tumor tissue
was available in 219 patients. Data obtained for each patient
included gender, age, site of distant metastasis according to the
American Joint Committee on Cancer (soft tissue metastasis vs.
pulmonary involvement vs. other visceral sites), presence of brain
metastasis, serum LDH level (normal vs. .upper limit of normal
[ULN]) and the date and cause of death, if applicable. Moreover,
time points of initiation of first-line chemotherapy and last follow-
up were collected. All patients had given their written informed
consent to have their data recorded by the CMMR. The aims and
methods of data collection by the CMMR have previously been
reported in detail [19].
Sequencing
Microdissection of formalin-fixed paraffin-embedded tumor
tissue was performed to obtain at least 50% tumor cells. After
digestion by proteinase K an amplicon containing the BRAF codon
600 was amplified by a polymerase-chain-reaction (PCR) assay
using forward primer 59-tcataatgcttgctctgatagga-39 and reverse
primer 59-ccaaaaatttaatcagtgga-39. PCR products were analyzed
on an agarose gel and purified using USBH ExoSAP-ITH
(Affymetrix, Santa Clara, CA). Sanger sequencing was performed
in reverse direction and sequences were analyzed with Mutation
Surveyor Version 3.20 (SoftGenetics, State College, PA). For all
samples which could not be clearly classified as mutant or wild-
type, PCR and sequencing was repeated.
Statistics
Overall survival time was calculated from the first application of
temozolomide or dacarbazine to the date of last follow-up or
death; only deaths due to melanoma were considered, whereas
patients who died from other causes were censored at the date of
death. Estimates of cumulative survival probabilities according to
Kaplan-Meier were described together with 95%-confidence
intervals and compared using log rank tests. Cox regression
analyses were used to determine the independent effects of
prognostic factors. All variables were considered in Cox regression
analyses and patients with missing data were excluded. Models
were established using backward and forward stepwise procedures.
Remaining non-significant factors were assessed for potential
confounding effects. Changes in the estimates of factors in a model
by more than 5% were taken as indicative for confounding.
Results of the Cox regression models were described by hazard
ratios (HR) together with 95%-confidence intervals, and p-values
were based on the Wald test. All Chi square tests were performed
2-sided using Fisher’s exact tests. Throughout the analysis, p-
values of less than 0.05 were considered statistically significant. All
analyses were carried out using SPSS Version 21 (IBM SPSS,
Chicago, Illinois, USA).
Results
Patients
215 of 219 patients with successful sequencing (98.2%) were
further analyzed. Median age was 64 years and 55% were male.
The majority of patients (66.0%) were classified as M1c stage
according to AJCC at start of systemic treatment (24.2% M1b and
9.8% M1a, respectively). During follow-up, 191 (88.8%) died from
melanoma. Median follow-up was 9 months for patients who died
and 46 months for those who were alive at the last follow-up. None
of the patients received treatment with BRAF or MEK inhibitors
during follow-up. A BRAF-V600 tumor mutation was detected in
89 patients (41.4%). 80.9% of mutations were V600E, 18.0% and
1.1% were V600K and V600M mutations, respectively.
After stratification according to the BRAF mutational status, a
comparison of both groups was performed to detect imbalanced
distribution of the remaining factors (Table 1). Significant
differences were found according to age with a higher proportion
of younger patients in the tumor BRAF mutant compared to the
BRAF wild-type group (31.5% vs. 15.1% younger than 50 years,
respectively). Moreover, the proportion of patients treated with
temozolomide was higher in the BRAF mutant group (43.8% vs.
26.2%). Both groups were well balanced for the remaining factors.
Additionally, correlations were observed between the treatment
with temozolomide and younger age (p = 0.001) and between
treatment with temozolomide and the presence of brain metastases
(p,0.001).
Survival Analysis
Median overall survival probability according to Kaplan-Meier
was 9 months. The presence of brain metastases (Figure 1A), the
M category according to AJCC and the serum LDH level
(Figure 1B) were associated with outcome (all p,0.001). The
largest difference in the one year survival was observed according
to cerebral involvement. Moreover, the presence of brain
metastases was associated with the lowest absolute 1 year survival
rate (18.1%). The best prognosis with a 59.5% 1-year survival rate
was observed in patients with distant metastasis limited to the soft-
tissue. The BRAF-V600 mutational status was not associated with
survival (p = 0.966; Figure 1C) and no differences in overall
survival were detected according to age (p= 0.938), gender
(p = 0.071) or to the cytotoxic agent used for therapy (dacarbazine
vs. temozolomide; p= 0.146). Complete results of clinical associ-
ations and univariate survival analysis are presented in Table 1.
In Cox regression analysis (Table 2) the presence of brain
metastases (HR 2.3; p,0.001) and an elevated serum LDH (HR
2.5; p,0.001) were the only factors, which independently
predicted survival. No prognostic relevance was observed accord-
ing to the BRAF mutational status.
Due to the observed correlations, we additionally performed the
survival analysis separately for 170 patients without brain
involvement (Table 3) and for the other 45 patients with brain
metastasis (Table 4).
Within both groups LDH remained the only independent factor
according to Cox regression analysis and the relative risk do die
from disease was still 2.3-fold increased in case of elevated LDH
(p= 0.014 and p,0.001 for patients with or without brain
metastasis, respectively). The slight trend for a better survival of
patients treated by dacarbazine compared to temozolomide, which
was observed in the entire cohort (p = 0.146), was completely lost
in these additional analyses performed separately for both groups
of patients.
Discussion
In the present study, we did not observe any difference in
survival after start of first-line chemotherapy according to the
BRAF mutational status. All institutional patients, who received
standard chemotherapy between the year 2000 and 2010 before
availability of BRAF inhibitors were included without further
selection. This is reflected by a high proportion of patients with
brain metastases (21%) or elevated LDH (32%). Up to our best
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knowledge this is the first prognostic study in which mutational
testing was performed retrospectively within the scope of this
analysis and was not built upon already available data acquired
from routine testing in therapeutic intention. Similar results were
reported by Edlundh-Rose et al. who analyzed survival in 215
metastasized melanoma patients with available follow-up data in
her study of 294 melanoma tumors from a total of 219 patients
[12]. In contrast, other prior studies observed worse survival of
patients with distant metastasis and BRAF-V600 mutant melanoma
[7–9,11]. Worse prognosis was explained by the constitutive
activation of the MAPK signaling pathway resulting in a more
dynamic growth pattern of tumor cells but confounding effects due
to patient selection could not be excluded in these studies [1,2].
Conflicting results about prognostic impact of BRAF-V600
tumor mutations are most likely due to patient selection and bias.
In prior prognostic studies, data about the mutational status were
mainly acquired due to intention to treat with a BRAF- or MEK
inhibitor. But to analyze the treatment-unrelated ‘‘natural’’ impact
of BRAF-V600 tumor mutations, only patients with confirmed
BRAF-mutations who finally did not receive subsequent inhibitor
treatment can be considered. Reasons for non-treatment with
inhibitors in BRAF-V600 mutant patients comprise applying of
exclusion criteria in the frame of clinical studies (e.g. elevated
LDH or development of brain metastases in the baseline imaging),
decrease of performance status or early death due to disease
progression. Therefore these patients represent a strongly biased
cohort towards worse prognosis.
Moreover, these BRAF-mutant patients included in prior
prognostic studies were compared to BRAF wild-type patients,
which in turn were biased towards favorable prognosis. The
analyzed cohorts comprised a large proportion of patients who
were tested in the frame of clinical trials in which patients with
cerebral metastases and high LDH levels were often excluded.
The only decisive factors for prognosis according to our analysis
were LDH and the kind of visceral involvement. Cerebral
involvement was more powerful than the visceral involvement
according to AJCC to predict prognosis as described by others
[20].
In our study we found several correlations between analyzed
factors which have to be discussed in more detail. The strong
correlation between the treatment schedule and the BRAF status
(p = 0.008) can be explained considering the following aspects:
According to institutional guidelines, temozolomide is favored over
dacarbazine in younger patients to avoid hospitalization for
intravenous therapy and in those with brain metastasis. The
appliance of these guidelines is reflected in our cohort by strong
correlations between the selection of temozolomide and younger
age (p = 0.001) or brain involvement (p,0.001), respectively. On
the other hand both patient characteristics are in turn correlated
with a high rate of BRAF V600 mutations. A higher rate of mutant
BRAF in younger patients was already reported in all larger studies
of the last 5 years [7–9,21] and this correlation was also observed
in our cohort (Table 1; p = 0.004). The association between a high
rate of BRAF V600 mutations and a high prevalence of brain
metastases is more controversial. A slightly higher rate of mutant
BRAF was observed in our patients with brain metastases
compared to those without (48.9% vs. 39.4%) but the difference
was statistically not significant. In literature, a strong correlation
was reported in the largest study, which analyzed this aspect thus
Figure 1. Univariate survival analysis. Kaplan Meier survival curves
according to (A) the presence of brain metastasis, (B) serum lactate
dehydrogenase (LDH) or (C) the BRAF-V600 mutational status. Censored
events are indicated by vertical lines.
doi:10.1371/journal.pone.0089218.g001
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far [9] in contrast to two prior studies [7,22]. Nevertheless, the
observed correlation between the selected treatment and the rate
of BRAF V600 mutations in the current study is therefore most
likely an indirect consequence of appliance of institutional
guidelines, which prefer temozolomide over dacarbazine in
younger patients and in patients with brain metastases (Figure 2).
The trend (p = 0.145) for a worse survival of patients treated
with temozolomide is also explained by the appliance of these
guidelines. In our cohort, 47.2% temozolomide treated patients
but only 7.7% dacarbazine treated patients had cerebral
involvement. If patients with brain metastases are excluded the
difference in survival according to the used agent is no longer
observed (p = 0.962). Moreover, no impact of the BRAF status on
survival was found in patients with (p = 0.575) or without
(p = 0.714) brain metastases if analyzed separately according to
cerebral involvement.
Table 2. Multivariate analysis for disease-specific death.
Prognostic factor Sample size (n =194) % Dead Relative risk (95%-CI#) p-value
Brain metastasis
No 153 (78.9%) 86.3% 1
Yes 41 (21.1%) 95.1% 2.5 (1.6, 3.8) P,0.001
Lactate Dehydrogenase
Normal 63 (32.5%) 87.0% 1
Elevated 131 (67.5%) 90.5% 2.3 (1.6, 3.2) P,0.001
#95%-CI = 95% confidence interval;
*21 patients had unknown values for LDH and were excluded; the model was adjusted for the confounding effects of the site of distant metastasis; no significant
interaction was detected.
doi:10.1371/journal.pone.0089218.t002
Table 3. Survival analysis for patients without brain involvement.
Univariate Analysis Multivariate Analysis*
n % % dead
1-year
survival rate [95%-CI#] (%) p Relative risk [95%-CI#] p
All patients 170 53.8 87.1 50.0 [42.4; 57.6]
BRAF-V600 mutations 0.714
Present 67 39.4 91.0 52.2 [40.2; 64.2]
Absent 103 60.6 84.5 48.5 [38.7; 58.3]
Gender 0.123
Male 92 54.1 90.2 45.3 [35.1; 55.5]
Female 78 45.9 83.3 55.6 [44.4; 66.8]
Age 0.878
,50 years 33 19.4 90.9 48.5 [31.4; 65.6]
50–59 years 32 18.8 84.4 52.1 [34.5; 69.7]
60–69 years 41 24.1 87.8 47.6 [32.1; 63.1]
$70 years 64 37.6 85.9 51.2 [38.9; 63.5]
Systemic treatment 0.962
Dacarbazine 132 77.6 85.6 49.4 [40.8; 58.0]
Temozolomide 38 22.4 92.1 51.9 [35.8; 68.0]
LDH ,0.001
Elevated 49 32.0 89.8 29.3 [16.4; 42.2] 2.3 [1.6; 3.4] ,0.001
Normal 104 68.0 84.6 56.2 [46.6; 65.8] 1.0
Missing 17
Site of distant metastasis 0.161
Soft tissue 28 16.5 82.1 59.5 [41.1; 77.9]
Only lung 59 34.7 96.6 49.2 [36.5; 61.9]
Other visceral 83 48.8 81.9 47.4 [36.6; 58.2]
# 95%-CI = 95% confidence interval; * 17 patients had unknown values for LDH and were excluded; the model was adjusted for the confounding effects of the site of
distant metastasis; no significant interaction was detected.
doi:10.1371/journal.pone.0089218.t003
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In conclusion, survival of melanoma patients receiving first line
treatment with either dacarbazine or temozolomide is associated
with the serum LDH level and cerebral involvement but not
dependent on the tumor BRAF-V600 mutational status.
Table 4. Survival analysis for patients with brain involvement.
Univariate Analysis Multivariate Analysis*
n % % dead
1-year
survival rate [95%-CI#] (%) p Relative risk [95%-CI#] p
All patients 45 100.0 95.6 18.7 [7.1; 30.3]
BRAF-V600 mutations 0.575
Present 22 48.9 90.9 15.6 [0.0; 31.5]
Absent 23 51.1 100.0 21.7 [4.8; 38.6]
Gender 0.344
Male 27 60.0 96.3 18.5 [3.8; 33.2]
Female 18 40.0 94.4 18.3 [0.0; 36.7]
Age 0.373
,50 years 14 31.1 92.9 17.8 [0.0; 37.6]
50–59 years 9 20.0 88.9 22.2 [0.0; 49.4]
60–69 years 11 24.4 100.0 36.4 [8.0; 64.8]
$70 years 11 24.4 100.0 0.0 na
$
Systemic treatment 0.618
Dacarbazine 11 24.4 100.0 9.1 [0.0; 26.2]
Temozolomide 34 75.6 94.1 21.8 [7.7; 35.9]
LDH 0.007
Elevated 14 34.1 92.9 0.0 na
$ 2.3 [1.2; 4.9] 0.014
Normal 27 65.9 96.3 22.2 [6.5; 37.9] 1.0
Missing 4
#95%-CI = 95% confidence interval;
$
na =not available.
*4 patients had unknown values for LDH and were excluded; no confounding effects were detected.
doi:10.1371/journal.pone.0089218.t004
Figure 2. Correlation between a high rate of BRAF V600 mutations and treatment with temozolomide. This unexpected correlation
observed in the present study (grey broken arrow) can be explained as an indirect consequence of the appliance of institutional guidelines for
treatment selection and established correlations (black arrows) between the rate of BRAF V600 mutations or other clinical features (grey rectangles)
reported in the literature and/or observed in the present study. The thickness of arrows illustrates the level of evidence for the given correlation.
doi:10.1371/journal.pone.0089218.g002
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